Home » Stocks » Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc. (ICPT)

Stock Price: $40.42 USD 0.66 (1.66%)
Updated Sep 25, 2020 4:00 PM EDT - Market closed
After-hours: $40.64 +0.22 (0.54%) Sep 25, 4:16 PM

Stock Price Chart

Key Info

Market Cap 1.33B
Revenue (ttm) 283.35M
Net Income (ttm) -339.26M
Shares Out 32.98M
EPS (ttm) -10.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 25, 2020
Last Price $40.42
Previous Close $39.76
Change ($) 0.66
Change (%) 1.66%
Day's Open 39.69
Day's Range 39.57 - 40.81
Day's Volume 495,491
52-Week Range 37.50 - 125.00

More Stats

Market Cap 1.33B
Enterprise Value 1.34B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 32.98M
Float 27.66M
EPS (basic) -10.38
EPS (diluted) -10.33
FCF / Share -6.72
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.52M
Short Ratio 6.95
Short % of Float 24.85%
Beta 1.61
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.70
PB Ratio 44.19
Revenue 283.35M
Operating Income -300.30M
Net Income -339.26M
Free Cash Flow -221.58M
Net Cash -5.38M
Net Cash / Share -0.16
Gross Margin 87.45%
Operating Margin -105.98%
Profit Margin -119.70%
FCF Margin -78.20%
ROA -25.19%
ROE -703.80%
ROIC -28.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (25)

Buy 7
Overweight 1
Hold 17
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$67.68*
(67.44% upside)
Low
46.0
Current: $40.42
High
140.0
Target: 67.68
*Average 12-month price target from 22 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue25218013124.952.781.741.622.451.81-
Revenue Growth40.15%37.3%424.85%796.87%59.7%7.4%-33.69%35.51%--
Gross Profit24817713024.952.781.741.622.451.81-
Operating Income-312-285-336-403-229-113-39.45-18.91-13.83-16.35
Net Income-345-309-360-413-226-283-67.79-43.64-12.74-15.09
Shares Outstanding31.6528.4625.0524.6623.6920.7818.036.283.333.33
Earnings Per Share-10.89-10.86-14.38-16.74-9.56-13.63-3.76-7.36-4.73-5.40
Operating Cash Flow-237-241-265-342-163-87.74-28.01-15.752.61-13.66
Capital Expenditures-1.14-0.17-10.39-5.08-5.94-4.64-1.63-0.04-0.06-0.03
Free Cash Flow-238-241-276-348-169-92.38-29.64-15.792.54-13.69
Cash & Equivalents65743641568962824014511017.7115.50
Total Debt532371356341----0.080.33
Net Cash / Debt12564.9159.2434862824014511017.6315.16
Assets75550948473965625415011219.4717.12
Liabilities70349046842453.6123.2667.9146.2722.038.80
Book Value51.5619.1316.3931560223182.4165.91-2.568.32
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Intercept Pharmaceuticals, Inc.
Country United States
Employees 583
CEO Mark E. Pruzanski

Stock Information

Ticker Symbol ICPT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ICPT
IPO Date October 11, 2012

Description

Intercept Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.